However, since the discovery of BRAF V600 somatic missense mutations in approximately 50% of malignant melanomas and at a lower frequency in a wide range of human cancers [7], there has been remarkable progress in the development of targeted therapies for unresectable and metastatic melanoma, with high response rates [5, 6]. The gene discussed is BRAF; the disease is metastatic melanoma.